Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Oxaliplatin With Radiation for Esophageal and GEJ Adenocarcinoma
NCT00711412Phase 2Completed
- Sponsor
- Northwestern University
- Start
- May 2006
- Primary completion
- May 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Northwestern University. Started May 2006; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00711412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00711412.